![](https://investorshub.advfn.com/uicon/182506.png?cb=1466612923)
Monday, July 01, 2013 7:27:38 AM
By Dow Jones Business News, July 01, 2013, 03:14:00 AM EDT
Vote up
Bayer AG (BAYN.XE) said Monday it is seeking approval from the U.S. and the E.U. to use its drug Nexavar to treat thyroid cancer.
MAIN FACTS:
-Nexavar, also known as sorafenib, is an oral drug developed and marketed by Bayer HealthCareand Onyx Pharmaceuticals Inc. ( ONXX ).
-The companies have applied to the U.S. Food & Drug Administration and the European Medicines Agency to use the drug to treat localized, advanced thyroid cancer or metastasis.
-"Especially for patients in the advanced stage, treatment options are lacking or very limited," Bayer's head of global development Dr. Kemal Malik said.
-Nexavar is already approved to treat liver cell cancer and advanced kidney cancer, Bayer said.
-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
07-01-130314ET
Copyright (c) 2013 Dow Jones & Company, Inc.
Read more: http://www.nasdaq.com/article/bayer-seeks-us-eu-approval-for-nexavar-to-treat-thyroid-cancer-20130701-00046#ixzz2XnB7sRgU
_______________________________________________________
ONXX
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM